Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: Results from a randomized phase 2 study Meeting Abstract
| Authors: | Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; McMillan, A. K.; Kim, T. M.; Kim, W. S.; Hertzberg, M.; Ozcan, M.; Penuel, E.; Cheng, J.; Hirata, J. M.; Ku, G.; Flowers, C. |
| Abstract Title: | Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) versus BR alone: Results from a randomized phase 2 study |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419700021 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.2821.2821 |
| Notes: | Meeting Abstract: 2821 -- Source: Wos |
